Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis

Julie A Murphy, Jacklyn A Harris, Andrew J CrannageSt Louis College of Pharmacy, St Louis, MO, USAAbstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including I...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Julie A Murphy, Jacklyn A Harris, Andrew J Crannage
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://doaj.org/article/6e1a90c822834423a44782c190dfd876
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6e1a90c822834423a44782c190dfd876
record_format dspace
spelling oai:doaj.org-article:6e1a90c822834423a44782c190dfd8762021-12-02T06:29:08ZPotential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis1176-63281178-2021https://doaj.org/article/6e1a90c822834423a44782c190dfd8762010-09-01T00:00:00Zhttp://www.dovepress.com/potential-short-term-use-of-oral-cladribine-in-treatment-of-relapsing--a5342https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Julie A Murphy, Jacklyn A Harris, Andrew J CrannageSt Louis College of Pharmacy, St Louis, MO, USAAbstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-modifying therapies for the treatment of relapsing-remitting MS. Cladribine, also known as 2-chlorodeoxyadenosine, is a synthetic adenosine deaminase-resistant purine nucleoside analog that preferentially depletes lymphocyte subpopulations. This sustained effect on lymphocytes is advantageous for patients with MS. CLARITY (CLAdRIbine Tablets Treating MS OrallY), a Phase III trial, has demonstrated that short-term oral cladribine decreases relapse rates and risk of disability progression in comparison with placebo. Cladribine was well tolerated in the study, with the most common adverse effects being headache, nausea, upper respiratory tract infections, and lymphocytopenia. An ongoing study is evaluating the efficacy and safety of the combination of oral cladribine and IFN-β products. A further ongoing study is examining the use of oral cladribine in clinically isolated syndrome and time to conversion to MS. Although the results of CLARITY are promising, the exact role of oral cladribine may be better defined with the completion of ongoing studies.Keywords: cladribine, multiple sclerosis, relapsing-remitting, oral, disease-modifying therapy Julie A MurphyJacklyn A HarrisAndrew J CrannageDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 619-625 (2010)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Julie A Murphy
Jacklyn A Harris
Andrew J Crannage
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
description Julie A Murphy, Jacklyn A Harris, Andrew J CrannageSt Louis College of Pharmacy, St Louis, MO, USAAbstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-modifying therapies for the treatment of relapsing-remitting MS. Cladribine, also known as 2-chlorodeoxyadenosine, is a synthetic adenosine deaminase-resistant purine nucleoside analog that preferentially depletes lymphocyte subpopulations. This sustained effect on lymphocytes is advantageous for patients with MS. CLARITY (CLAdRIbine Tablets Treating MS OrallY), a Phase III trial, has demonstrated that short-term oral cladribine decreases relapse rates and risk of disability progression in comparison with placebo. Cladribine was well tolerated in the study, with the most common adverse effects being headache, nausea, upper respiratory tract infections, and lymphocytopenia. An ongoing study is evaluating the efficacy and safety of the combination of oral cladribine and IFN-β products. A further ongoing study is examining the use of oral cladribine in clinically isolated syndrome and time to conversion to MS. Although the results of CLARITY are promising, the exact role of oral cladribine may be better defined with the completion of ongoing studies.Keywords: cladribine, multiple sclerosis, relapsing-remitting, oral, disease-modifying therapy
format article
author Julie A Murphy
Jacklyn A Harris
Andrew J Crannage
author_facet Julie A Murphy
Jacklyn A Harris
Andrew J Crannage
author_sort Julie A Murphy
title Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
title_short Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
title_full Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
title_fullStr Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
title_full_unstemmed Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
title_sort potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/6e1a90c822834423a44782c190dfd876
work_keys_str_mv AT julieamurphy potentialshorttermuseoforalcladribineintreatmentofrelapsingremittingmultiplesclerosis
AT jacklynaharris potentialshorttermuseoforalcladribineintreatmentofrelapsingremittingmultiplesclerosis
AT andrewjcrannage potentialshorttermuseoforalcladribineintreatmentofrelapsingremittingmultiplesclerosis
_version_ 1718399875779919872